Page 41 - Read Online
P. 41

Page 326                                Genvigir et al. J Transl Genet Genom 2020;4:320-55  I  http://dx.doi.org/10.20517/jtgg.2020.37

              Ref.   [27]  [33]   [34]     [35]     [42]        [36]   [43]    [39]     [14]



              Clinical outcomes  No association of UGT1A7   -57T>G variant with   leukopenia  -  No association of UGT1A7   c.622C>T variant with   gastrointestinal adverse   events  -  Treatment with MMF 2 g/ d and UGT1A8 c.830AA  genotype were associated   with occurrence of  infections, but not diarrhea,   or blood disorders  -  No association of UGT1A8   c.830G>A variant with  adverse events (diarrhea or   leukopenia)  No association of UGT1A8   -









              Pharmacokinetics  No association of   UGT1A7*2 and   UGT1A7*3 variants with   MPA pharmacokinetics  UGT1A7 c.622CC  genotype was associated   exposure to MPAG   No association of  UGT1A8*2 variant with   daytime or nighttime   MPA pharmacokinetics   UGT1A8*2/*2 (GG)  genotype was associated  c.518C>G and c.830G>A  with higher MPA AUC 0-12 , variants with AR  in cyclosporine-treated   No association of   UGT1A8 c.518C>G   variant with MPA or   MPAG pharmacoki







                 -                -            with higher  (AUC 0-12 )  -  -         patients
             Immunosuppressive   regimen  MMF Cyclosporine Tacrolimus  Sirolimus  Corticosteroids   One-year follow-up  MMF  Tacrolimus  Corticosteroids   At day 28  MMF  Cyclosporine Tacrolimus  Sirolimus  Up to 115-month follow-  up  MMF  Tacrolimus  Corticosteroids  MMF Cyclosporine Tacrolimus  Sirolimus  Corticosteroids   MMF  Tacrolimus  Corticosteroids  At day 28  MMF Cyclosporine Tacrolimus  Corticosteroids   MMF  Cyclosporine Tacrolimus  Corticosteroids   One-year









                 284 pediatric and young   adult patients (USA)  80 adult patients (Japan)  256 adult patients  (France)  127 adult patients  (China)  74 adult patients   (Brazil)  72 adult patients (Japan)  38 pediatric patients   (USA)  338 adult patients  185 patients  (France)
              Population









              Study design  Retrospective (Case-  Control), multicenter  Prospective  Retrospective  Prospective  Retrospective  Prospective  Retrospective (Case-  Control)  Prospective, multicenter  (FDCC Study)  Prospective (included   multicenter Apomygre   study)







              Allele frequency  UGT1A7*2: 8%  UGT1A7*3: 28%  c.622C: 37%  c.622C: 19%  UGT1A8*2: 58%  c.830A: 4%  c.518G: 25%  c.830A: 2%  c.518G: 26%






                 -                                  -


              Variant     rs11692021 (c.622T>C)  UGT1A7*2 [c.387T>G   c.391C>A (rs17863778)   UGT1A7*3 (c.387T>G +   c.391C>A + c.392G>A +   rs17863762 (UGT1A8*3,   (UGT1A8*2, c.518C>G)

                 rs7586110  (-57T>G)   (rs17868323) +   + c.392G>A   (rs17868324)]  c.622T>C)  c.830G>A)  rs1042597




              Gene   UGT1A7                         UGT1A8
   36   37   38   39   40   41   42   43   44   45   46